Journal of Endocrinology and Reproduction

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Genetics of Medullary Thyroid Carcinoma


Affiliations
1 Department of Endocrinology, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai-600113, India
2 Ontogenie et Reproduction, CRBR, CHUL, 2705 Boul W Lauira, Laval University Stc Roy, que, GIV 4G2, Canada
     

   Subscribe/Renew Journal


Existing modes of diagnosis and therapy for medullary thyroid carcinoma (MTC) have limitations, informations on the genetics of familial medullary thyroid carcinoma (FMTC), a constituent of multiple endocrine neoplasia II (MEN II) syndrome may help to understand the etiology of the disease and to design gene therapy. Association between specific mutations in ret protooncogene to specific phenotypes of MEN II subjects provide vital line of due for the diagnosis of the disease. Screening of suspected/potent carriers of ret (rearranged during transformation) mutations will help to decide about the time and course of treatment. Gene therapy for MTC appears to be imminent and this review attempts to provide a comprehensive account of informations from more than hundred research articles published in this area.

Keywords

Calcitonin, Familial Medullary Thyrold Carcinoma, Gene Therapy, Immuno Therapy, Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia, Ret Protooncogene.
Subscription Login to verify subscription
User
Notifications
Font Size


Abstract Views: 263

PDF Views: 0




  • Genetics of Medullary Thyroid Carcinoma

Abstract Views: 263  |  PDF Views: 0

Authors

M. Michael Aruldhas
Department of Endocrinology, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai-600113, India
N. Kalpana
Department of Endocrinology, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai-600113, India
G. Vengatesh
Department of Endocrinology, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai-600113, India
K. Sakhila Banu
Ontogenie et Reproduction, CRBR, CHUL, 2705 Boul W Lauira, Laval University Stc Roy, que, GIV 4G2, Canada
P. Govindarajulu
Department of Endocrinology, Dr. ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai-600113, India

Abstract


Existing modes of diagnosis and therapy for medullary thyroid carcinoma (MTC) have limitations, informations on the genetics of familial medullary thyroid carcinoma (FMTC), a constituent of multiple endocrine neoplasia II (MEN II) syndrome may help to understand the etiology of the disease and to design gene therapy. Association between specific mutations in ret protooncogene to specific phenotypes of MEN II subjects provide vital line of due for the diagnosis of the disease. Screening of suspected/potent carriers of ret (rearranged during transformation) mutations will help to decide about the time and course of treatment. Gene therapy for MTC appears to be imminent and this review attempts to provide a comprehensive account of informations from more than hundred research articles published in this area.

Keywords


Calcitonin, Familial Medullary Thyrold Carcinoma, Gene Therapy, Immuno Therapy, Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia, Ret Protooncogene.



DOI: https://doi.org/10.18519/jer%2F2001%2Fv5%2F98611